US approves updated Pfizer, Moderna shots targeting Omicron / Photo: Joseph Prezioso - AFP/File
-
Malians tell of torture and killings by army, Russian fighters
-
EU-China spacecraft takes off on mission to probe solar winds
-
Under Trump pressure, EU eyes deal to end trade standoff
-
'We're here solely to play football,' insists North Korean coach
-
Putin trip aims to show China ties unshakeable after Trump pomp
-
Hanoi hits the brakes on petrol bike ban
-
Japan economy grows faster than expected in first quarter
-
World Cup glory attracts superstar coaches into international battle
-
Stuttering Sabalenka seeks to set down marker at Roland Garros
-
'Little' Freiburg chasing glory in debut European final
-
Villa inspired by former heroes as they target Europa League glory
-
Irrepressible Sinner primed for career Grand Slam at Roland Garros
-
China market for Nvidia AI chips to open 'over time': Huang
-
Asian markets cautious, oil dips after Trump holds off on Iran attack
-
Three killed in San Diego mosque shooting, both suspects dead
-
Love, lust and gnomes as top UK flower show bursts into bloom
-
Fans of historic DC park wary of Trump plan to 'beautify' city
-
As bee population collapses, US apiarists fear research cuts
-
Lights out for Cuban students as blockade bites
-
Campaigners warn Italy's gutted rape bill could help assailants
-
Libyan ex-prison boss faces ICC war crimes hearing
-
Argentine scientists lay first traps in hantavirus hunt
-
Star of Rome's 'sexy priest' calendar admits: 'I was never a priest'
-
Harry Styles fans to splash over £1 bn on London concerts: Barclays
-
Bolivia protest sees violent clashes, looting in La Paz
-
Trump says held off on new Iran attack, upbeat for agreement
-
Los Angeles World Cup workers vow strike over ICE guarantees
-
Three killed in San Diego mosque shooting, two attackers dead
-
US to screen for Ebola at airports, one American in DR Congo infected
-
Aussie Scott officially set for 100th straight major at US Open
-
Pep Guardiola to leave Man City at end of the season - reports
-
Neymar back in Brazil squad for fourth World Cup
-
Arsenal on the brink of Premier League title after nervy Burnley win
-
Oil rises, global stocks mixed as markets track Iran developments
-
World Cup winner Pavard confirms Marseille exit
-
Trump says holding off on new Iran attack
-
Cuba warns of 'bloodbath' if US attacks; Washington adds sanctions
-
Trump says delaying Iran attack at request of Gulf leaders
-
Cuba warns of 'bloodbath' if US attacks and Washington issues sanctions
-
After mayor's murder, Mexico battles to bring peace
-
Trump admin creates $1.7 bln fund to compensate allies prosecuted under Biden
-
Pelicans name Mosley as coach, two weeks after Magic firing
-
Hyderabad qualify for IPL play-offs along with Gujarat
-
'Girl in the River Main' identified 25 years on, father arrested
-
Musk loses blockbuster OpenAI suit as jury says too late
-
SNC Scandic Coin and Biconomy: Regulated real-world assets meet global trading infrastructure
-
Judge allows gun as evidence in Mangione healthcare exec murder trial
-
First attack on Arab nuclear site sends warning to Gulf, US
-
Oil rises, bond yields weigh on stocks
-
Hormuz tanker traffic edges higher after wartime low
US approves updated Pfizer, Moderna shots targeting Omicron
US health officials on Wednesday authorized updated Covid-19 vaccinations by Moderna and Pfizer-BioNTech that specifically target the latest strains of the Omicron variant, with the goal of jump-starting a new booster campaign.
The two updated booster shots aimed at providing "better protection against Covid-19 caused by the Omicron variant" are approved for people age 12 and above for the Pfizer shot and 18 and older for Moderna, the Food and Drug Administration (FDA) said in a statement.
This new generation of anti-Covid vaccines targets both the original strain of coronavirus and the BA.4 and BA.5 lineages, the subvariants of Omicron that are causing the most cases in the United States and which the FDA predicts will circulate in the coming months.
Earlier this summer the US health department announced it had purchased 105 million doses from Pfizer and 66 million from Moderna for use over the fall and winter.
The vaccines have yet to be recommended by the Centers for Disease Control and Prevention, the nation's health protection agency. But an independent panel of experts is scheduled to be convened by the CDC on Thursday to discuss the updates.
CDC director Rochelle Walensky will be in charge of giving the final green light.
The new versions of the vaccines could potentially be available in the United States as early as next week.
"Receiving a booster that specifically targets the Omicron BA.4/.5 variant, currently the most prevalent strain of SARS-CoV-2, is an important public health measure that people can take to help protect themselves, especially as we head into a season filled with indoor gatherings," Moderna chief executive Stephane Bancel said in a statement.
The vaccines currently in circulation target the initial strain of the virus that first appeared in Wuhan, China. But they have gradually proven to be less effective against the variants that have appeared over time, due to rapid evolution of the virus.
In contrast to the Alpha and Delta variants, which eventually waned, Omicron and its subvariants have come to dominate infections worldwide in 2022.
Pfizer and Moderna have also filed for approval of their updated vaccines with the European Medicines Agency.
K.Hassan--SF-PST
